Aldoxorubicin
- Generic Name
- Aldoxorubicin
- Drug Type
- Small Molecule
- Chemical Formula
- C37H42N4O13
- CAS Number
- 1361644-26-9
- Unique Ingredient Identifier
- C28MV4IM0B
- Background
Aldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.
- Indication
Investigated for use/treatment in solid tumors.
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
Phase 2
Completed
- Conditions
- Metastatic Soft Tissue SarcomaLocally Advanced Soft Tissue SarcomaUnresectable Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT01514188
- Locations
- 🇺🇦
Vinnytsya Regional Clinical Oncologic Dispensary, Surgical Department, Vinnytsya, Ukraine
🇮🇳Jehangir Clinical Development Centre Pvt Ltd, Pune, Maharashtra, India
🇮🇳Christian Medical College, Vellore, Tami Nadu, India
Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01337505
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
INNO-206 in Patients With Small Cell Lung Cancer (SCLC)
Phase 2
Withdrawn
- Conditions
- Small Cell Lung Cancer
- First Posted Date
- 2007-05-14
- Last Posted Date
- 2012-02-09
- Lead Sponsor
- CytRx
- Registration Number
- NCT00472771
- Locations
- 🇺🇸
New York Oncology Hematology, P.C., Albany, New York, United States
🇺🇸Dayton Oncology and Hematology, Kettering, Ohio, United States
🇺🇸Mary Crowley Medical Research Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath